Evidence map›Paper›PMID 22683846›Full record

ReviewMutation research

MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis.

Alberto Izzotti, Cristina Cartiglia, Vernon E Steele, Silvio De Flora

Open access · greenAbstract readReview
In one paragraph

Review in Mutation research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Activation of the miR-34a-Mediated SIRT1/mTOR Signaling Pathway by Urolithin A Attenuates D-Galactose-Induced Brain Aging in Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer.Medical oncology (Northwood, London, England) · 2014
    Article
  17. MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  18. Article
  19. Article
  20. MicroRNA and cancer chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Alberto IzzottiDepartment of Health Sciences, University of Genoa, Genoa, 16132, Italy.
Cristina CartigliaDepartment of Health Sciences, University of Genoa, Genoa, 16132, Italy.
Vernon E SteeleNational Cancer Institute, Rockville, MD 20892, USA.
Silvio De FloraDepartment of Health Sciences, University of Genoa, Genoa, 16132, Italy. Electronic address: sdf@unige.it.
University of Genoa · ITNational Cancer Institute · US

Funding

NCI NIH HHS N01 CN053301NCI NIH HHS N01-CN53301
6 · The paper itself

Abstract

MicroRNAs (miRNAs) have been implicated in many biological processes, cancer, and other diseases. In addition, miRNAs are dysregulated following exposure to toxic and genotoxic agents. Here we review studies evaluating modulation of miRNAs by dietary and pharmacological agents, which could potentially be exploited for inhibition of mutagenesis and carcinogenesis. This review covers natural agents, including vitamins, oligoelements, polyphenols, isoflavones, indoles, isothiocyanates, phospholipids, saponins, anthraquinones and polyunsaturated fatty acids, and synthetic agents, including thiols, nuclear receptor agonists, histone deacetylase inhibitors, antiinflammatory drugs, and selective estrogen receptor modulators. As many as 145 miRNAs, involved in the control of a variety of carcinogenesis mechanisms, were modulated by these agents, either individually or in combination. Most studies used cancer cells in vitro with the goal of modifying their phenotype by changing miRNA expression profiles. In vivo studies evaluated regulation of miRNAs by chemopreventive agents in organs of mice and rats, either untreated or exposed to carcinogens, with the objective of evaluating their safety and efficacy. The tissue specificity of miRNAs could be exploited for the chemoprevention of site-specific cancers, and the study of polymorphic miRNAs is expected to predict the individual response to chemopreventive agents as a tool for developing new prevention strategies.

Indexed as

DietAnimalsAnticarcinogenic AgentsAntimutagenic AgentsChemopreventionHumansMicroRNAsNeoplasmsPharmaceutical PreparationsVitaminsAnticarcinogenic AgentsAntimutagenic AgentsMicroRNAsPharmaceutical PreparationsVitamins

Identifiers

PMID22683846
PMCPMC4716614
OpenAlexW2029927562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.